View in EDS

T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma.

Saved in:
Bibliographic Details
Title: T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma.
Authors: Barceló C; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Sisó P; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Maiques O; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., García-Mulero S; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain., Sanz-Pamplona R; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain., Navaridas R; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Megino C; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Felip I; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Urdanibia I; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Eritja N; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Soria X; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain., Piulats JM; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Penin RM; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain., Dolcet X; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Matías-Guiu X; Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Martí RM; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: marti@medicina.udl.cat., Macià A; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain. Electronic address: amacia@irblleida.cat.
Source: The Journal of investigative dermatology [J Invest Dermatol] 2020 Jun; Vol. 140 (6), pp. 1253-1265. Date of Electronic Publication: 2019 Dec 23.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31877318
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF<superscript>V600E</superscript> Melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Barceló+C%22">Barceló C</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Sisó+P%22">Sisó P</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Maiques+O%22">Maiques O</searchLink>; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22García-Mulero+S%22">García-Mulero S</searchLink>; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Sanz-Pamplona+R%22">Sanz-Pamplona R</searchLink>; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Navaridas+R%22">Navaridas R</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Megino+C%22">Megino C</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Felip+I%22">Felip I</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Urdanibia+I%22">Urdanibia I</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Eritja+N%22">Eritja N</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Soria+X%22">Soria X</searchLink>; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Piulats+JM%22">Piulats JM</searchLink>; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Penin+RM%22">Penin RM</searchLink>; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Dolcet+X%22">Dolcet X</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain.<br /><searchLink fieldCode="AU" term="%22Matías-Guiu+X%22">Matías-Guiu X</searchLink>; Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Martí+RM%22">Martí RM</searchLink>; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: marti@medicina.udl.cat.<br /><searchLink fieldCode="AU" term="%22Macià+A%22">Macià A</searchLink>; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain. Electronic address: amacia@irblleida.cat.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220426720%22">The Journal of investigative dermatology</searchLink> [J Invest Dermatol] 2020 Jun; Vol. 140 (6), pp. 1253-1265. <i>Date of Electronic Publication: </i>2019 Dec 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0426720 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1523-1747 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220022202X%22">0022202X </searchLink><i>NLM ISO Abbreviation: </i>J Invest Dermatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31877318
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jid.2019.11.014
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1253
    Titles:
      – TitleFull: T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Barceló C
      – PersonEntity:
          Name:
            NameFull: Sisó P
      – PersonEntity:
          Name:
            NameFull: Maiques O
      – PersonEntity:
          Name:
            NameFull: García-Mulero S
      – PersonEntity:
          Name:
            NameFull: Sanz-Pamplona R
      – PersonEntity:
          Name:
            NameFull: Navaridas R
      – PersonEntity:
          Name:
            NameFull: Megino C
      – PersonEntity:
          Name:
            NameFull: Felip I
      – PersonEntity:
          Name:
            NameFull: Urdanibia I
      – PersonEntity:
          Name:
            NameFull: Eritja N
      – PersonEntity:
          Name:
            NameFull: Soria X
      – PersonEntity:
          Name:
            NameFull: Piulats JM
      – PersonEntity:
          Name:
            NameFull: Penin RM
      – PersonEntity:
          Name:
            NameFull: Dolcet X
      – PersonEntity:
          Name:
            NameFull: Matías-Guiu X
      – PersonEntity:
          Name:
            NameFull: Martí RM
      – PersonEntity:
          Name:
            NameFull: Macià A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2020 Jun
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1523-1747
          Numbering:
            – Type: volume
              Value: 140
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: The Journal of investigative dermatology
              Type: main
ResultId 1